Bone disease drug discovery: Examining the interactions between osteoblast and osteoclast

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 2, 2008, Pages 239-251

  Sun, Sengen ^a  

^a Division of Medicinal Chemistry   (United States)

Author keywords

Anabolic; Antiresorptive; Bisphosphonate; Bone disease; Cathepsin K; Chloride channel 7; Integrin; Osteoblast; Osteoclast; Osteoporosis; Receptor activator of NF B; Receptor activator of NF B ligand; Vacuolar ATPase; Wnt pathway

Indexed keywords

ALENDRONIC ACID; ANTIOXIDANT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBONATE DEHYDRATASE II; CATHEPSIN K; CHLORIDE CHANNEL; CLODRONIC ACID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESTROGEN; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TAMOXIFEN; TILUDRONIC ACID; TOREMIFENE; UNINDEXED DRUG; VITAMIN D; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID;

ARTHROPATHY; BONE DISEASE; BONE REMODELING; BREAST CANCER; CELL FUNCTION; CELL INTERACTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; ESTROGEN DEFICIENCY; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VERTEBRA FRACTURE;

BONE AND BONES; BONE DISEASES; DRUG EVALUATION, PRECLINICAL; HUMANS; OSTEOBLASTS; OSTEOCLASTS;

EID: 39649099367     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.2.239     Document Type: Review

References (98)

1. Prevalence of Disabilities and Associated Health Conditions Among Adults - United States, 1999. MMWR 2001;50:120-5. Available from: URL: www.cdc.gov/mmwr/preview/mmwrhtml/mm5007a3.htm [last accessed January 7, 2008]
2. Teitelbaum SL. Osteoclasts: what do they do and how they do it? Am J Parhol 2007;170:427-35
3. Fuller K, Kirstein B, Chambers TJ. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond) 2007;112:567-75
4. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003;38:605-14
5. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-64
6. Blair HC, Robinson LJ, Zaidi M. Osteoclast signaling pathways. Biochem Biophys Res Commun 2005;328:728-38
7. Shinohara M, Takayanagi H. Novel osteoclast signaling mechanisms. Curr Osteoporos Rep 2007;5:67-72
8. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289:1501-4
9. Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: impact on bone disease. Histol Histopathol 2004;19:1325-44
10. Sabokbar A, Athanasou NS. Generating human osteoclasts from peripheral blood. Methods Mol Med 2003;80:101-11
11. Takeshita S, Faccio R, Chappel J, et al. c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages. J Biol Chem 2007;282:18980-90
12. Faccio R, Takeshita S, Colaianni G, et al. M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721. J Biol Chem 2007;282:18991-9
13. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular disease. J Am Med Assoc 2004;292:490-5
14. Karsdal MA, Martin TJ, Bollerslev J, et al. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007;22:487-94
15. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007;19:376-82
16. Glass DA, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007;148:2630-4
17. Glass DA, Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 2006;73:43-84
18. Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 2007;5:73-80
19. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. Clin Invest 2006;116:1202-9
20. Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007;40:1581-7
21. Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39-47
22. Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006;7:1603-15
23. Civitelli R, Napoli N, Armamento-Villareal R. Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 2007;5:8-13
24. Colon-Emeric CS, Saag KG. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006;20:695-706
25. Boonen S. Bisphosphonate efficacy and clinical trials for postmenopausal osteoporosis: similarities and differences. Bone 2007;40:S26-31
26. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of Alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
27. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol 2007;19:364-9
28. Chestnut CH. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Drugs 2006;66:13510-9
29. Lane NE. Long-term effects of treatment with alendronate for patients with osteoporosis. Nat Clin Pract Rheumatol 2007;3:426-7
30. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
31. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005;328:709-20
32. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005;328:746-50
33. Xie Y, Ding H, Qian L, et al. Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro. Bioorg Med Chem Lett 2005;15:3267-70
34. Balas F, Manzano M, Horcajada P, Vallet-Regi M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 2006;128:8116-7
35. Casolaro M, Casolaro I. Novel therapeutic agents for bone resorption. Part 1. Synthesis and protonation thermodynamics of poly(amino-amine)s containing bisphosphonate residues. Biomacromolecules 2006;7:3417-27
36. Sondergaard BC, Oestergaard S, Christiansen C, et al. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007;56:2674-8
37. Sun L, Moonga B, Zaidi M, Huang CL. Molecular physiology and pharmacology of calcitonin. Cell Mol Biol 2006;52:33-43
38. Tanaka S, Suzuki H, Yamauchi H, et al. Signal transduction pathways of calcitonin/calcitonin receptor regulating cytoskeletal organization and bone-resorbing activity of osteoclasts. Cell Mol Biol 2006;52:19-23
39. Neer RM, Arnaud CD, Zanchetta RJ, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
40. Chen P, Miller PD, Recker R, et al. Increases in bone mineral density correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007;22:1173-80
41. Bilezikian JP, Rubin MR. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep 2006;4:5-13
42. Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-79
43. Barret-Connor E, Cauley J, Kulkarni P, et al. Risk-benefit profile for raloxifene: 4-year data from the multiple outcomes of raloxifene evaluation randomized trial. J Bone Miner Res 2004;19:1270-5
44. Roux C. Antifracture efficacy of strontium ranelate in postmenopausal osteoporosis. Bone 2007;40:S9-11
45. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007;40:S5-8
46. Choudhary S, Halbout P, Alander C, et al. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvements of prostaglandins. Bone Miner Res 2007;22:1002-10
47. Reginster JY. Managing the osteoporosis patient today. Bone 2007;40:S12-8
48. Raisz LG. Maintaining the life-long vitality and integrity of skeletal tissue. Bone 2007;40:S1-4
49. Reginster JY, Meunier PJ, Roux C, et al. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral antifracture efficacy over 5 years in post menopausal osteoporotic women. Osteoporos Int 2006;17(Suppl 2):514
50. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229
51. Fleischmann R, Iqbal I. Risk:benefit profiles of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007;24:239-54
52. Ospelt C, Cay S. Antirheumatic drugs and gene signatures. Curr Opin Invetig Drugs 2007;8:385-9
53. Sueleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmcol Rep 2007;59:247-58
54. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3-27
55. Hamdy NA. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr Opin Investig Drugs 2007;8:299-303
56. Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 2005;3:121-5
57. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo controlled study of AMG-162, fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66
58. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31
59. 3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005;90:2022-8
60. 3 antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004;47:4829-37
61. 3 inhibitors. Bioorg Med Chem 2007;15:3783-800
62. 3 antagonists as novel anticancer agents. J Med Chem 2006;49:4526-34
63. Xu J, Cheng T, Feng HT, et al. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis. Histol Histopathol 2007;22:443-54
64. Niikura K, Nakajima S, Takano M, Yamazaki H. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats. Bone 2007;40:888-94
65. Niikura K. Compatative analysis of the effects of a novel vacuolar adenosine 5′-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats. J Periodontol 2007;77:1211-6
66. Niikura K. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol 2007;60:555-62
67. Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res 2005;20:1579-88
68. Biasotti B, Dallavalle S, Merlini L, et al. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase. Bioorg Med Chem 2003;11:2247-54
69. Menche D, Hassfeld J, Sasse F, et al. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor. Bioorg Med Chem Lett 2007;17:1732-5
70. Sorensen MG, Henriksen K, Neutzsky-Wulff AV, et al. Diphyllin, a novel and natural potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 2007;22:1640-8
71. Lloyd MD, Thiyagarajan N, Ho YT, et al. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochem 2005;44:6858-66
72. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. Bioorg Med Chem Lett 2005;15:567-71
73. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14
74. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-53
75. Karsdal MA, Henriksen K, Sorensen MG, et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005;166:467-76
76. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of Cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007;8:315-23
77. Cai J, Jamieson C, Moir J, Rankovic Z. Cathepsine K inhibitors, 2000-2004. Expert Opin Ther Patents 2005;15:33-48
78. Deaton DN, Kumar S. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Prog Med Chem 2004;42:245-375
79. Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Develop 2005;8:619-30
80. Medivir Files Clinical Trial Application to Start Phase I With MIV-701. Available from: URL: www.genengnews.com/news/bnitem.aspx?name=10940381 [last accessed January 7, 2008]
81. Novel Drug Shows "Very Promising" Results as Osteoporosis Treatment. Available from: URL: www.medscape.com/viewarticle/563067 [last accessed January 7, 2008]
82. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metasis. J Natl Cancer Inst 2002;94:17-25
83. Ishibashi O, Niwa S, Kadoyama K, Inui T MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006;79:1657-60
84. Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:231-7
85. Chan A, Van Bezooijen RL, Lowik CW. A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 2007;8:293-8
86. Ominsky MS, Warmington KS. Sclerostin monoclonal antibody treatment increases bone strength in aged osteopenic ovariectomized rats. Proc Am Soc Bone Miner Res 2006;28:Abs1161
87. Sclerostin Antibody in Phase I Trial. Available from: URL: www.amgen.com/ investors/pipe.jsp [last accessed January 7, 2008]
88. Margutti S, Laufer SA. Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem 2007;2:1116-40
89. AMG 108 in Phase II Trial. Available from: URL: clinicaltrials.gov/ct/ show/NCT00369473 [last accessed January 7, 2008]
90. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through down-regulation of NFATc1. J Bone Miner Res 2005;20:653-62
91. Wakamatsu K, Nanki T, Miyasaka N, et al. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005;7:R1348-59
92. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B: an emerging theme in anti-inflammatory therapies. Mol Interv 2002;2:22-35
93. Tarner IH, Mueller-Ladner U, Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2007;3:336-45
94. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007;22:1603-11
95. Schacht E, Dukas L, Richy F. Combined therapy in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neutral Interact 2007;7:174-84
96. Novartis Corporate. Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss. USPTO Application #20060281714
97. Léger S, Baylya CI, Blacka WC, et al. Primary amides as selective inhibitors of cathepsin K. Bioorg Med Chem Lett 2007;17:4328-32
98. Xiong Y, Zhao M, Wang C, et al. Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates. J Med Chem 2007;50:3340-53